Form 4: Dianthus Therapeutics Executive Sells Shares

Dianthus Therapeutics EVP, CFO & CBO, Ryan Savitz, reported a transaction involving the sale of 8,224 shares of common stock.

Summary

• Ryan Savitz, Executive Vice President, Chief Financial Officer & Chief Business Officer of Dianthus Therapeutics, Inc., engaged in a stock transaction on April 9, 2026.
• The transaction involved the acquisition of 8,224 shares of common stock at a price of $17.88 per share.
• Concurrently, 8,224 shares of common stock were disposed of at a weighted average price of $89.84 per share, with individual sales ranging from $89.75 to $89.95.
• These transactions were executed as part of a Rule 10b5-1 trading plan adopted on December 30, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can sometimes be perceived negatively, the execution of a pre-planned Rule 10b5-1 trading plan and the significant profit margin on the sale suggest a structured financial decision rather than a negative signal about the company's future.

Positives

• The executive executed a pre-planned Rule 10b5-1 trading plan, indicating structured and potentially pre-determined financial management.
• The sale occurred at a significantly higher price ($89.84 average) than the acquisition price ($17.88), suggesting a profitable transaction for the executive.

Negatives

• A significant number of shares (8,224) were sold by a key executive, which could be perceived negatively by the market.
• The sale price of $89.84 is a weighted average, and the full details of individual sales at specific prices are to be provided upon request.

Risks

• Potential for negative market perception due to a key executive selling a substantial number of shares.
• The Rule 10b5-1 plan implies a pre-determined selling strategy, which might not align with immediate company performance news.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance. The future outlook is primarily related to the vesting schedule of stock options and the expiration of those options.

Management Comments

• The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
• The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan by an executive like Ryan Savitz is a common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The significant difference between the acquisition and sale price suggests a potentially successful stock option grant or prior investment.

Stakeholder Impact

• Shareholders: May interpret the sale as a sign of reduced confidence by management, although the Rule 10b5-1 plan mitigates this concern. The sale at a profit is a positive for the executive.
• Employees: The vesting schedule of stock options for the executive is detailed, which is part of their compensation structure.
• Creditors: No direct impact mentioned.
• Suppliers/Customers: No direct impact mentioned.

Next Steps

• The executive's stock options continue to vest monthly until January 1, 2028, subject to continued service.
• The executive may continue to execute trades under the Rule 10b5-1 plan if it remains active.
• Full information regarding the number of shares sold at each separate price within the range will be provided to the Issuer, any security holder, or the SEC staff upon request.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Ryan Savitz, Executive Compensation, Beneficial Ownership